ReviewCancers2023
The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making-The Urological Perspective.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07011342 (Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Late endocrine-metabolic complications in survivors of young adult and adult-onset cancers: comprehensive evaluation and strategies for management. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical review.Journal of endocrinological investigation · 2026Review
- Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617.European journal of nuclear medicine and molecular imaging · 2026Article
- The Socio-Demographic Characteristics of Patients Diagnosed with Prostate Cancer Treated in South Africa's Only Rural Central Hospital in 2020: A Cross-Sectional Study Protocol.Healthcare (Basel, Switzerland) · 2026Article
- Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).Theranostics · 2026Review
- Review
- A Case Report and Literature Review: When Should We Treat the Seminal Vesicles in Prostate Cancer?Cureus · 2025Article
- Therapeutic Consequences ofCancers · 2025Article
- The Role of PSMA PET Imaging in Prostate Cancer: Current Applications and Future Directions.Current urology reports · 2025Review
- Supraclavicular nodal metastasis at primary staging of prostate cancer usingEJNMMI reports · 2025Article
- Structure-Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions.ACS omega · 2025Article
- Review
- The potential of gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography as a main diagnostic tool in prostate cancer staging.Central European journal of urology · 2025Review
- Androgen Signaling in Prostate Cancer: When a Friend Turns Foe.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Standardized template for clinical reporting of PSMA PET/CT scans.European journal of nuclear medicine and molecular imaging · 2024Article
- Early treatment response assessment with [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Article
- Multiparametric MRI for characterization of the tumour microenvironment.Nature reviews. Clinical oncology · 2024Review
- Targeting glutamate carboxypeptidase II in IBD.Advances in pharmacology (San Diego, Calif.) · 2024Review
- Contrast enhanced CT on PET/CT imaging in clinical routine: an international survey.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen (PSMA) PET use in prostate cancer treatment has recently become a routinely used imaging modality by urologists. New, established data regarding its performance in different stages of prostate cancer, as well as gaining clinical knowledge with new tracers, drives the need for urologists and other clinicians to improve the utilization of this tool. While the use of PSMA PET/CT is more common in metastatic disease, in which it outperforms classical imaging modalities and drives treatment decisions and adjustments, recently, it gained ground in localized prostate cancer as well, especially in high-risk disease. Still, PSMA PET/CT might reveal lesions within the prostate or possibly locoregional or metastatic disease, not always representing true cancer when utilized in earlier stages of the disease, potentially adding diagnostic burden and changing treatment decisions. As urological treatment options advance toward focal treatments in localized organ-confined prostate cancer, recent reports suggest the utilization of PSMA PET/CT in treatment planning and follow-up and even when choosing active surveillance. This review aims to reveal the current perspective of urologists regarding its daily use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.